Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2882694 | 0.99 | FFAR4 (0.49) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL13378117 | 0.94 | FFAR4 (0.50) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL13009739 | 0.90 | PTGER1 (0.48) | FFAR4PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL6700856 | 0.88 | FFAR4 (0.51) | FFAR4GCGRS1PR1S1PR3S1PR5 | |
| SCHEMBL4650113 | 0.88 | FFAR4 (0.62) | FFAR4 | |
| SCHEMBL2889790 | 0.86 | FFAR4 (0.41) | FFAR4FFAR1GCGR | |
| SCHEMBL13378123 | 0.86 | MRGPRX4 (0.46) | FFAR4PTGER1PTGER2MRGPRX4KMT2A | |
| SCHEMBL14396569 | 0.84 | FFAR4 (0.44) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL13010023 | 0.82 | FFAR4 (0.42) | FFAR4PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL13009831 | 0.80 | PTGER1 (0.56) | FFAR4FFAR1PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700653-B2 | Halogen-substituted aminodicarboxylic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700653-B2 | Halogen-substituted aminodicarboxylic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700653-B2 | Halogen-substituted aminodicarboxylic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7067694-B2 | Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2006-06-27 | — | — | US | disclosed |
| US-20060111444-A1 | Novel halogen-substituted aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-1368303-B1 | HALOGEN-SUBSTITUTED AMINO DICARBOXYLIC ACID DERIVATIVES AS MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2004-12-15 | — | — | EP | disclosed |
| US-20040092593-A1 | Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1368303-A1 | HALOGEN-SUBSTITUTED AMINO DICARBOXYLIC ACID DERIVATIVES AS MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES | Bayer Aktiengesellschaft (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070460-A1 | HALOGEN-SUBSTITUTED AMINO DICARBOXYLIC ACID DERIVATIVES AS MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092593-A1 | Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BCAT2, DDC, AADAT | FFAR4 321/4885FFAR1 199/4885PTGER1 1640/4885 |
| US-20060111444-A1 | Novel halogen-substituted aminodicarboxylic acid derivatives | FABP3, PPARD, FABP1 | FFAR4 45/4885FFAR1 53/4885PTGER1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.